FCA
FLNA

Fortis Capital Advisors’s Filana Therapeutics FLNA Stock Holding History

Fortis Capital Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,259
Closed -$24.3K – 417
2025
Q4 		$24.3K Sell
12,259
-304
-2% -$973 ﹤0.01% 311
2025
Q3 		$36.6K Buy
+12,563
New +$28.9K 0.01% 281

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Fortis Capital Advisors's FLNA Position: Q1 2026 in Review

Fortis Capital Advisors sold out of Filana Therapeutics (FLNA) in Q1 2026, closing a stake of 12,259 shares — an estimated $24.3K sold.

Fortis Capital Advisors first reported a position in FLNA in Q3 2025 and held it in 2 quarters. The position peaked at $36.6K in Q3 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Fortis Capital Advisors reported no remaining Filana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fortis Capital Advisors sold 12,259 Filana Therapeutics shares in Q1 2026, an estimated $24.3K.
  • Fortis Capital Advisors first reported a position in Filana Therapeutics in Q3 2025 and held it in 2 quarters.
  • Fortis Capital Advisors's Filana Therapeutics position peaked at $36.6K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Fortis Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.